l e t t e r s CRISPR-Cas9-based genome editing enables the rapid genetic manipulation of any genomic locus without the need for gene targeting by homologous recombination. Here we describe a conditional transgenic approach that allows temporal control of CRISPR-Cas9 activity for inducible genome editing in adult mice. We show that doxycycline-regulated Cas9 induction enables widespread gene disruption in multiple tissues and that limiting the duration of Cas9 expression or using a Cas9 D10A (Cas9n) variant can regulate the frequency and size of target gene modifications, respectively. Further, we show that this inducible CRISPR (iCRISPR) system can be used effectively to create biallelic mutation in multiple target loci and, thus, provides a flexible and fast platform to study loss-of-function phenotypes in vivo.
The type II bacterial CRISPR (clustered, regularly interspaced, short palindromic repeats)-Cas9 (CRISPR-associated protein) system can be engineered to induce RNA-directed, double-strand DNA breaks or single-strand 'nicks' using a mutated form of Cas9 (Cas9 D10A or Cas9n) [1] [2] [3] . CRISPR-Cas9 technology has been used to create heritable changes in the mouse genome, dramatically decreasing the time required to develop genetically engineered mouse models (GEMMs) [4] [5] [6] . However, homozygous germline mutations often result in embryonic lethality or developmental defects and are not tissue specific, limiting the utility of such models for studying gene function in adult tissues. Additionally, although CRISPR-Cas9-directed mutagenesis in zygotes enables rapid generation of compound mutants, genetic mosaicism in the founders and allele segregation limits the ability to produce large cohorts of experimental mice without further intercrossing. Here, we describe a rapid tetracycline (doxycycline)-regulated approach that enables inducible in vivo genetic manipulation of multiple loci from a single transgene.
We and others have previously used a recombinase-mediated cassette exchange approach to deliver tetracycline-inducible cDNAs and short hairpin (sh)RNAs to a defined genomic locus, thus reducing founder effects associated with random integration 7, 8 . As proof-ofprinciple demonstration, we chose to target the well-characterized adenomatous polyposis coli (Apc) tumor suppressor, as germline loss of Apc is embryonic lethal 9 , whereas disruption of Apc in the intestine of adult mice results in the development of hyperplastic polyps 10 . We first generated single guide RNAs (sgRNAs) targeting murine Apc that contained a unique 'seed' region in the 12 bp immediately upstream of the NGG protospacer-adjacent motif (PAM) sequence. We also developed sgRNAs to target Trp53 (Supplementary Fig. 1a ), a gene whose inactivation often occurs in APC mutant colon cancer. Analysis of transfected mouse embryonic stem cells (ESCs) using Surveyor assays showed the expected modifications ( Supplementary Fig. 1a ). We next cloned each U6-sgRNA cassette into a new 'col1a1-targeting construct, upstream of TRE 3G -regulated GFP-IRES-Cas9' (c3GIC9; Fig. 1a ), which facilitates the generation of constructs carrying multiple U6-sgRNA cassettes in series. As a control for sgRNA expression and Cas9-mediated DNA cleavage, we generated an sgRNA targeting a nongenic region on mouse chromosome 8 (CR8).
We produced KH2 ESC clones targeting CR8, Apc and Trp53 and tested for the presence of insertions and deletions (indels) by Surveyor assay. Both GFP induction (linked to Cas9; Fig. 1b ) and target modification occurred within 2 d of doxycycline treatment ( Fig. 1c ) and increased with time ( Fig. 1d ). In addition, targeted ESC clones carrying both Apc and Trp53 sgRNAs in tandem showed equivalent indel frequency ( Fig. 1c) , indicating that the presence of two sgRNAs in series does not influence the efficiency of Cas9-mediated cleavage. To directly assess the capability of our system to induce biallelic modification in multiple genes, we treated two independent c3GIC9-Apc/Trp53 parental ESC clones with doxycycline for 10 d, removed doxycycline and allowed single clones to expand in the absence of Cas9 expression. Of 154 individual ESC clones analyzed by Sanger sequencing, greater than 94% displayed biallelic disruption at a given locus ( Fig. 1e) . Both alleles showed a frameshift/in-frame indel ratio of close to 2:1 (expected by chance; Fig. 1f ), implying that selection for loss-of-function mutations did not account for the high frequency of indels observed. Most importantly, more than 90% of all clones assessed showed biallelic modification at both Apc and Trp53 (Fig. 1g , left) and nearly half of all clones contained frameshift disruptions at each of the four alleles ( Fig. 1g, right) . These data suggest that the iCRISPR system can be used to induce disruption of multiple targets from a single transgene.
In some cases we identified ESC clones that showed evidence of indels in the absence of doxycycline (see asterisk, Fig. 1c ). Of 39 clones analyzed, 13 (33%) displayed some level of off-doxycycline mutagenesis. However, the frequency of 'off-dox' mutations did not l e t t e r s increase with continuous culture 11 (Fig. 1d ), suggesting they arise due to leaky expression of Cas9 during transfection. Thus, we screened up to six clones for each targeting event, to identify nonmutated clones for mouse production.
CRISPR-Cas9 genome editing can also cause 'off-target' mutations 12 . We identified potential off-target loci ( Supplementary Table 1 ) and assessed their mutation in doxycycline-treated c3GIC9-Apc/ Trp53 ESCs. Of all off-target predictions for sg-Trp53 (12 sites) and sg-Apc (6 sites) sgRNAs, only one of the Trp53 predictions (an intron of Elk3) showed evidence of indels ( Supplementary Fig. 1b ). This region was modified in every doxycycline-treated Trp53 sgRNA clone ( Supplementary Fig. 1c) , implying it is a bona fide off-target site. Of the 18 predicted off-targets, only OFT7 (Elk3 intron) displayed 100% complementarity in the 12-bp seed region upstream of the PAM ( Supplementary Table 1 ), in line with previous observations and suggesting the 3′ region of sgRNAs dictate target specificity 1 .
Off-target mutagenesis can be reduced in cultured cells by using the Cas9n 'nickase' variant in combination with closely spaced sgRNAs targeting alternate DNA strands, providing increased specificity for the intended locus 3 . We cloned sgRNAs to pair with existing sgRNAs for Apc and Trp53 (Supplementary Fig. 1a ) and generated targeted ESC clones carrying each paired combination with a TRE 3G -regulated Cas9n transgene. As expected, induction of Cas9n promoted indels for both Trp53 (Supplementary Fig. 1c ) and Apc (Supplementary Fig. 1d ) but eliminated mutational events at the (Elk3) sg-Trp53 off-target site (Supplementary Fig. 1c ). Our survey was not genome-wide, and thus we cannot rule out the possibility that there are other regions affected by the sgRNAs/Cas9 complexes. However, these data show that use of the 'paired nickase' approach can produce conditional knockouts while reducing undesired genomic modifications.
We next produced transgenic mice carrying c3GIC9 targeting CR8, Apc and Apc/Trp53 as well c3GIC9n targeting Apc (Apc n ). Breeding of founders confirmed that each of the targeted alleles was transmitted in Mendelian ratios suggesting no toxicity during embryonic development ( Supplementary Table 2 ). Still, even small amounts of leaky Cas9 expression would be expected to induce germline mutation events. Sequencing revealed that only 16/166 loci (9.6%) of the offspring carried heterozygous mutations in CR8, Apc or Trp53. Within each strain, these heterozygous mutations were identical, suggesting they arose from rare events in ESCs that contribute to the germline of the founder, rather than independent, spontaneous events during breeding. Thus, leaky Cas9 expression during ESC clone generation can occasionally induce doxycycline-independent mutagenesis, but it is readily manageable by selecting appropriate F 1 progeny for strain propagation.
Conditional deletion of Apc in the mouse intestine induces hyperplastic proliferation and blocks differentiation, leading to rapid intestinal dysfunction and death 13 . To determine whether the CRISPR-Cas9 system could recapitulate conditional Apc knockout phenotypes in vivo, we treated 4-to 5-week-old R26-rtTA/c3GCI9 bitransgenic animals with doxycycline and monitored them over time. Surveyor analysis of intestinal villi after 10 d of doxycycline showed expected gene alterations (Supplementary Fig. 2a ) and immunostaining confirmed Apc and p53 protein loss ( Fig. 2a ). Of note, we observed some p53-positive cells and rare instances of increased staining, perhaps reflecting deletion of a region that regulates protein stability ( Fig. 2a , arrow). Those animals carrying Apc-targeted sgRNAs showed a 40-to 60-fold induction of the Wnt target genes Axin2 and Lgr5 and a dramatic (130-fold) increase in the proto-oncogene cMyc (Supplementary Fig. 2b) . Mirroring the molecular response, histology revealed dramatic hyperproliferation, crypt expansion (Ki67), a marked reduction in differentiation (Keratin 20) and ectopic production of lysozyme-positive npg l e t t e r s Paneth cells ( Fig. 2b and Supplementary Fig. 2c ), as expected following acute deletion of Apc 13 . Surprisingly, the Cas9n-paired sgRNA approach was as efficient at producing Apc mutations as Cas9 ( Supplementary Fig. 2a ), promoted a similar or greater increase in Wnt target gene expression ( Supplementary Fig. 2b ) and produced an identical intestinal phenotype (Fig. 2b) .
To more closely evaluate iCRISPR function over time, we exploited the fact that Apc inactivation induces a measurable morphological (spheroid) change in cultured intestinal organoids 14 . We isolated intestinal crypts from bitransgenic mice and assessed organoid morphology at different times following doxycycline addition. In vitro CRISPR induction for as little as 2 d led to the production of undifferentiated spheroids ( Fig. 2c , not shown) whose frequency increased with time ( Fig. 2d) . D7 doxycycline-treated cultures were virtually 100% spheroid and showed complete loss of full-length Apc protein with a corresponding increase in nonphosphorylated β-catenin, a downstream consequence of Apc loss ( Fig. 2e and Supplementary  Fig. 3b ). Cultures derived from doxycycline-treated c3GIC9-Apc/ Trp53 tandem mice showed near complete loss of p53 ( Fig. 2e and Supplementary Fig. 3) , further confirming the approach is effective for inactivation of multiple genes.
Interestingly, p53 expression in organoid cultures and intestine was mosaic, potentially reflecting in-frame deletions that do not cause loss of protein expression or cells that did not modify the Trp53 locus ( Fig. 2a,e and Supplementary Fig. 3 ). To comprehensively assess the frequency of indels produced following Cas9 or Cas9n induction, we sequenced each target locus in gDNA from the intestine and thymus of doxycycline-treated mice at an average depth of 55,000 reads/ sample. Both tissues showed a high frequency (50-85%) of target gene modification following 10 d of doxycycline ( Fig. 3a) , although the sizes and types of indels varied between each locus and tissue ( Fig. 3b and Supplementary Fig. 4 ). Cas9n in combination with paired Apc-targeted sgRNAs showed a bias toward deletion events compared to the single Apc-targeted sgRNA (Supplementary Fig. 4c) , and a significant increase in deletion size ( Fig. 3b and Supplementary  Fig. 4a,d ; intestine, P = 0.0002; thymus, P < 0.0001). Consistent with observations from ESCs, c3GIC9 tandem mice showed concordant mutation of both Apc and Trp53 genes (Fig. 3c , R 2 = 0.972).
Cas9 mutagenesis can produce both frameshift and in-frame indels that should, in principle, occur at a ratio of 2:1. Because in-frame deletions can produce functional proteins, the relative abundance of frameshift mutations in the tissue can indicate whether loss of gene function has a positive, negative or neutral impact on cell fitness. Consistent with this idea, Apc and Tp53 inactivation produce no selective advantage in ESCs, and both loci showed a predicted 2:1 ratio of frameshift to in-frame deletions (Fig. 1f) . Conversely, Apc inactivation produces a substantial selective advantage in the intestine, and intestinal tissue from sgApc/Cas9 mice displayed a strong bias for Apc truncations (97% frameshift mutations; Fig. 3d ). In these same animals, p53 inactivation produces little additional advantage in the time frame of analysis 15 , and, consequently, the frequency of frameshift indels remained near the predicted 2/3 frequency (72%). Remarkably, although disruption of Apc conferred a strong selective advantage and disruption of p53 did not, both loci showed equivalent CRISPR-mediated modification (Fig. 3a) , implying that the system can be used to study 'fitness neutral' mutations.
As seen in ESCs and organoids, Cas9-induced mutagenesis in vivo was time dependent, as Cas9 expression for 4 d induced significantly fewer mutations and reduced overall disease burden in the intestine (Supplementary Fig. 5 ; intestine, P < 0.0001; thymus, P = 0.03). Thus, varying the duration of Cas9 expression by timing doxycycline exposure provides a further level of control for altering gene function in vivo. Moreover, the ability to limit Cas9 expression may reduce toxicity and off-target effects associated with constitutive expression of sgRNA-Cas9 complexes, which can associate with thousands of genomic sequences 16 .
In our system the spatial induction of mutagenesis is dictated by where the rtTA allele, and thus Cas9, is expressed. Hence, strategies Apc Apc/Trp53 CR8 npg l e t t e r s that restrict rtTA to defined tissues provide a means to produce tissuespecific gene disruption. To explore the potential for Cas9-induced genome editing in other tissues we used hydrodynamic transfection to express rtTA3 in a restricted and mosaic fashion in the liver of c3GIC9-Apc n mice. Histological analyses showed expected cytoplasmic and nuclear accumulation of total and nonphosphorylated β-catenin specifically within GFP-positive hepatocytes (Supplementary Fig. 6 ). Thus, by controlling the expression of rtTA by either focused delivery (above) or using Cre-dependent systems 17 , the CRISPR system can be adapted to producing tissue-specific and conditional gene deletions in vivo. Taken together, our data show that doxycyclinedependent Cas9 or Cas9n induction in vivo induces target gene alterations that can recapitulate the effects of traditional conditional knockout approaches.
Recent studies have described the application of CRISPR-Cas9mediated genome editing in vivo using viral delivery or DNA transfection [18] [19] [20] [21] . Although they enable rapid CRISPR-based editing to produce gene modifications and chromosomal rearrangements, such methodologies are restricted to those tissues that can be efficiently accessed by exogenous constructs (i.e., liver, lung, brain). From a mouse-modeling standpoint, the iCRISPR platform is conceptually analogous to inducible Cre-based systems (i.e., CreER) though the effectiveness of each is difficult to directly compare. First, unlike the deletions created by loxP-based alleles, CRISPR-Cas9 relies on imprecise DNA repair by nonhomologous end joining (NHEJ), and thus generates a heterogeneous population of genetic mutants. In theory, the frequency of 'null' alleles can be increased through the use of sgRNAs targeting the coding region of an essential protein domain and/or using paired sgRNAs to increase deletion size (Fig. 3b) . Second, the efficiency of Cre-mediated deletion varies between genomic regions and the size of the recombination event, whereas sgRNA sequence or variation in NHEJ efficiency may influence CRISPR-Cas9 mutagenesis. Importantly, we do not see the iCRISPR approach as replacing Cre/loxP-based conditional knockouts, but rather providing a flexible and complementary alternative to study gene function in vivo, either when traditional methods are not applicable (e.g., for creating specific genetic truncations), or sufficiently rapid or scalable.
In R26-rtTA mice, TRE 3G -mediated Cas9 induction is strong in the intestine, skin and thymus, and although the TRE 3G promoter shows some mosaicism in adult mice, given appropriate rtTA expression (e.g., by direct delivery or alternate transgenic strains), it can induce gene disruption in other tissues, such as the liver (Supplementary  Fig. 6 ). The incorporation of alternate TRE promoters or Cre-dependent TRE-LSL-Cas9 transgenes, analogous to those produced for tissuespecific shRNA expression 17 , should enable inducible mutagenesis in a wider range of tissues, thereby allowing tissue-restricted conditional gene disruption during development or in adults. Furthermore, the iCRISPR platform is adaptable to Cas9-mediated gene regulation via transcriptional repression (CRISPRi) or activation (CRISPRa) using dCas9-KRAB and dCas9-VP64 variants, respectively 22, 23 . These systems offer a powerful approach to simultaneously regulate the expression of multiple genes without mutational heterogeneity, however, they are yet to be fully evaluated in vivo and, unlike Cas9, do not induce the permanent genetic changes frequently associated with disease.
Finally, our work suggests that use of paired sgRNAs in combination with Cas9n can drive robust loss-of-function phenotypes in vivo while reducing off-target mutagenesis, making it the system of choice for most applications. Although this approach requires the expression of two sgRNAs per target, the c3GIC9n targeting vector can accommodate at least six U6-sgRNA cassettes without loss of on-target efficiency (Supplementary Fig. 7) . Of course, increasing the number of genomic targets will also increase the complexity and heterogeneity of mutations, and thus, the analysis of strains that target many genes is likely to be complicated and best suited to cancer studies where such changes are positively selected. Regardless, inducible CRISPR-Cas9-mediated genome editing provides a simple strategy to develop conditional, genetic 'deletion' models in less than 6 months, providing a flexible, fast and low-cost platform to study gene function in vivo.
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Animals.
Production of mice and all treatments described were approved by the Institutional Animal Care and Use Committee (IACUC) at Memorial Sloan Kettering Cancer Center (NY), under protocol number 11-06-012. ESCderived mice were produced by blastocyst injection by the MSKCC transgenic core facility. Animals were maintained on a mixed C57B6/129 and progeny from breeding were genotyped for specific alleles (R26-rtTA and col1A1) using primers and protocols previously described 17, 24 . Doxycycline was administered via food pellets (625 mg/kg) (Harlan Teklad). Animal studies were not blinded. For detection of p53 protein, animals were euthanized 4 h following 6Gy whole body irradiation. For hydrodynamic plasmid delivery 12.5 µg of pCAGs-rtTA3 plasmid was mixed with sterile 0.9% sodium chloride solution.
Mice were injected with a total amount of sodium chloride/plasmid mix corresponding to 10% of the body weight into the lateral tail vein within 5-7 s.
Cloning. hCas9 (from pX330) or hCas9n (pX335) was cloned into the col1a1targeting vector downstream of the TRE3G-GFP-IRES. Sequences encoding guide RNAs were cloned into pX330 and pX335 for initial validation 1 . U6 promoter + guide RNA pairs were PCR amplified (sequences in Supplementary Table 3 ) and cloned (NsiI/SbfI) into an NsiI site upstream of the TRE3G promoter. The NsiI site re-forms upstream of the U6-sgRNA cassette and can be used for sequential addition of sgRNAs. The col1a1-TRE3G-GFP-IRES-Cas9 (c3GIC9) and c3GIC9n targeting vectors cannot be deposited at Addgene due to restrictions over distribution of plasmids containing the TRE3G promoter but will be made available upon request.
ESC targeting. All ESCs were maintained on irradiated feeders in M15 media containing LIF as previously outlined 24 . Two days following transfection cells were treated with media containing 150 µg/ml hygromycin and individual surviving clones were picked after 9-10 d of selection. Two days after clones were picked, hygromycin was removed from the media and cells were cultures in standard M15 thereafter. To confirm single copy integration at the col1a1 locus, we first validated expected integration by multiplex col1a1 PCR 24 , and second, confirmed the presence of a single GFP cassette using the Taqman copy number assay, according to the manufacturer's instructions (Invitrogen).
Immunohistochemistry and immunofluorescence. Tissue, fixed in freshly prepared 4% paraformaldehyde for 24 h, was embedded in paraffin and sectioned by IDEXX RADIL (Columbia, MO). Sections were rehydrated and unmasked (antigen retrieval) by either: (i) heat treatment for 10 min in a pressure cooker in 10 mM Tris/1 mM EDTA buffer (pH 9) containing 0.05% Tween 20 or (ii) proteinase K treatment (200 µg/ml) for 10 min at 37 °C (lysozyme staining The intestine was then cut into 5 mm pieces and placed into 10 ml cold 5 mM EDTA-PBS and vigorously resuspended using a 10 ml pipette. The supernatant was aspirated and replaced with 10 ml EDTA and placed at 4 °C on a benchtop roller for 10 min. This was then repeated for a second time for 30 min. The supernatant was aspirated and then 10 ml of cold PBS was added to the intestine and resuspended with a 10 ml pipette. After collecting this 10 ml fraction of PBS containing crypts, this was repeated and each successive fraction was collected and examined underneath the microscope for the presence of intact intestinal crypts and lack of villi. The 10 ml fraction was then mixed with 10 ml DMEM Basal Media (Advanced DMEM F/12 containing Pen/Strep, Glutamine, B27 (Invitrogen 17504-044), 1 mM Nacetylcysteine (Sigma-Aldrich A9165-SG)) containing 10 U/ml DNase I (Roche, 04716728001) and filtered through a 100 µm filter into a BSA-coated (1%) tube. It was then filtered through a 70 µm filter into a BSA-coated (1%) tube and spun at 1,200 r.p.m. for 3 min. The supernatant was aspirated and the cell pellet mixed with 5 ml basal media containing 5% FBS and centrifuged at 650 r.p.m. for 5 min. The purified crypts were then resuspended in basal media and mixed 1:10 with Growth Factor Reduced Matrigel (BD, 354230). 40 µl of the resuspension was plated in a 48-well plate and placed in a 37°C incubator to polymerize for 10 min. 250 µl of small intestinal organoid growth media (basal media containing 50 ng/ml EGF (Invitrogen PMG8043), 100 ng/ml Noggin (Peprotech 250-38), and 500 ng/ml R-spondin (R&D Systems, 3474-RS-050)) was then laid on top of the Matrigel. Where appropriate, media was supplemented with 0.5 µg/ml doxycycline (higher concentrations of doxycycline are toxic to organoids).
Maintenance. Media was changed on organoids every 2 d, and they were passaged 1:4 every 5-7 d. To passage, the growth media was removed and the Matrigel was resuspended in cold PBS and transferred to a 15 ml falcon tube. The organoids were mechanically disassociated using a p1000 or a p200 pipette and pipetting 50-100 times. 7 ml of cold PBS was added to the tube and pipetted 20 times to fully wash the cells. The cells were then centrifuged at 1,000 r.p.m. for 5 min and the supernatant was aspirated. They were then resuspended in GFR Matrigel and replated as above. For freezing, after spinning the cells were resuspended in Basal Media containing 10% FBS and 10% DMSO and stored in liquid nitrogen indefinitely.
Protein analysis. Small intestine organoids were grown in 300 µl of Matrigel in one well each of a 6-well dish containing 3 ml of growth media for 4 d post-passage, then treated with 125 ng/ml adriamycin for 4 h to induce p53 expression. Organoids were then recovered from the Matrigel using several rinses with cold PBS. Organoid pellets were lysed with Lamelli buffer. Antibodies used for western blot analysis were: anti-APC (1:400, FE9 clone, Millipore #MABC202), anti-nonphosphorylated β-catenin (1:1,000, #8814, Cell Signaling Technology), anti-p53 (1:500, #NCL-p53-505, Novocastra) and anti-actin-HRP (1:10,000, #ab49900, Abcam).
RNA isolation and qPCR. For small intestine samples, villi and crypts were harvested from the proximal duodenum (~1 inch) by scraping with a glass slide. Villi/crypt pellets were lysed with a wand homogenizer in 1 ml of Trizol (Invitrogen, 15596-026) RNA was extracted according to the manufacturer's instructions and contaminating DNA was removed by DNase treatment for 10 min and column purification (Qiagen RNeasy). cDNA was prepared from 1 µg total RNA using Taqman reverse transcription kit (Applied Biosystems, #N808-0234) with random hexamers. Quantitative PCR detection was performed using SYBR green reagents (Applied Biosystems) using primers specific to Axin2, Lgr5, Myc ( Supplementary Table 3 ).
Mutation detection by SURVEYOR assay. Cas9-induced mutations were detected using the SURVEYOR Mutation Detection Kit (Transgenomic/IDT). Briefly, an approximately 500 bp region surrounding the expected mutation site was PCR-amplified using Herculase II (600675, Agilent Technologies). PCR products were column purified (Qiagen) and subjected to a series of melt-anneal temperature cycles with annealing temperatures gradually npg
